Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.

Related Articles

Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.

Pathol Res Pract. 2016 Dec;212(12):1194-1198

Authors: Papageorgiou SG, Tsiodras S, Siakallis G, Bazani E, Spathis A, Poulakou G, Korkolopoulou P, Panayiotides I, Pappa V

Abstract
Anti-CD20-based chemo-immunotherapeutic regimens have been suggested to assist in the management of Epstein-Barr virus (EBV)-induced hemophagocytic lymphohistiocytosis (HLH) and EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD), by reducing EBV viral load and EBV-induced inflammation. Herein we report a fatal EBV-related HLH in the context of Hodgkin lymphoma (HL)-like Richter's transformation of B chronic lymphocytic leukemia (B-CLL), two months after rituximab treatment. The complex balance between EBV driven T-cell stimulation and immunosuppressive therapy in the context of multiple immune deficits is discussed.

PMID: 28340951 [PubMed - indexed for MEDLINE]

http://ift.tt/2oc5adv